Enter inventor name

Eric T Sun

This inventor holds 30 USPTO granted patents, primarily in Retroviral Protease Inhibitors. Top assignees: G.d. Searle & Company, Astrazeneca Canada Inc., Agouron Pharmaceuticals, Inc.. Active years: 1993-2007.

USPTO Granted Patents = 30

% Patents Active = 73.3

Average Co-Inventor Count = 4.6

ph-index = 7

Forward Citations = 126(Granted Patents)

Location History:

San Deigo, CA (US) (1996)
Buffalo Grove, IL (US) (1993 - 1997)
San Diego, CA (US) (1994 - 2007)

Company Filing History:

23 out of 1,323

G.d. Searle & Company

patents

3 out of 14

Astrazeneca Canada Inc.

patents

1 out of 174

Agouron Pharmaceuticals, Inc.

6. 3 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1993-2007

Loading Chart...

Areas of Expertise:

Retroviral Protease Inhibitors

Amino Acid Derivatives

Pain Management

Sulfonyl Urea Compounds

Pharmaceutical Compositions

GnRH Agents

Hydroxyethylamino

Sulfamic Acid Derivatives

Succinoylamino Compounds

Non-Peptide Agents

Imidazo Compounds

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7232817 - α- and β-amino acid hydroxyethlamino sulfonyl urea derivatives useful as retroviral protease inhibitors (2007-06-19),

2. 7202258 - α- and β-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors (2007-04-10),

3. 7199158 - Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors (2007-04-03),

4. 7037941 - Alpha-and Beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors (2006-05-02),

5. 7030161 - α-and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors (2006-04-18),

6. 6951886 - Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors (2005-10-04),

7. 6903132 - Non-peptide GnRH agents, pharmaceutical compositions and methods for their use (2005-06-07),

8. 6777561 - Compounds (2004-08-17),

9. 6683648 - &agr;- and &bgr;-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors (2004-01-27),

10. 6515024 - Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors (2003-02-04),

11. 6444678 - &agr;- and &bgr;-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors (2002-09-03),

12. 6403585 - &agr;-and &bgr;-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors (2002-06-11),

13. 6387949 - Substituted urea compounds useful in pain management (2002-05-14),

14. 6376534 - Compounds useful in pain management (2002-04-23),

15. 6337398 - Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors (2002-01-08),

Title: Inventor Eric T Sun - Revolutionizing Technology in San Diego

Introduction: Eric T Sun is a visionary inventor based in San Diego, CA, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Eric T Sun holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and innovative thinking.

Career Highlights: With a career spanning over two decades, Eric T Sun has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have had a significant impact on various industries.

Collaborations: Throughout his career, Eric T Sun has collaborated with top scientists, engineers, and researchers to bring his ideas to life, fostering a culture of innovation and creativity in the projects he undertakes.

Conclusion: Eric T Sun's relentless pursuit of innovation and his passion for pushing the boundaries of technology make him a true pioneer in the world of inventions, with a lasting legacy that continues to inspire future generations of inventors.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]